Lebanon Roadside Bomb Wounds 4 Israeli Troops as War Continues to Escalate

Abivax Crashes Most On Record After Cancer Cases In Trial Data Spooks Wall Street French biotech Abivax suffered its largest intraday decline on record after reporting new data on its lead experimental inflammatory bowel disease drug, which showed cancer cases among patients in the clinical trial. The new data certainly point to regulatory headwinds and raise the risk profile for approval. Abivax's ABTECT maintenance data showed strong efficacy readout, with both once-daily obefazimod doses meeting the primary endpoint at week 44. Clinical remission rates were 50.8% for the 25 mg dose...

Gold Selloff Seen As "Stop-Loss Liquidation Positioning Reset", Not Fundamentally Driven Gold’s break below key technical support of 4050 to the 4023 low in New York trading on Wednesday appears driven primarily by stop-loss liquidation and positioning rather than a material deterioration in macro fundamentals, according to UBS.  As the bank's trader Marcus Millis writes, "the move flushed out long exposure and left positioning looking more balanced, reducing the immediate risk of further forced selling." However, he cautions, the broader trading backdrop remains challenging. That's because with front-end USD rates expected to stay...

Armor, Ammunition And Battlefield Adaptation Goldman Sachs analyst Sam Burgess, who covers European defense companies including Airbus, BAE Systems, Rheinmetall, Renk, Rolls-Royce, Safran, Leonardo, Thales, and Dassault Aviation, held a call with retired German Lieutenant General Andreas Marlow to provide clients with greater color on the rapidly evolving modern battlefield and its implications for defense-sector investment decisions. Marlow said the war in Ukraine has exposed a slew of weaknesses in conventional armies rather than rendering them obsolete. He said future combat will depend on integrated forces combining armor, infantry, artillery, all...